Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment

Biomaterials. 2016 Nov:108:44-56. doi: 10.1016/j.biomaterials.2016.09.001. Epub 2016 Sep 4.

Abstract

Finding effective cures against aggressive malignancy remains a major challenge in cancer chemotherapy. Here, we report a "tadpole"-like peptide by covalently conjugating the alanine-alanine-asparagine "tail" residual to the cyclic tumor homing peptide iRGD (CCRGDKGPDC) to afford nRGD, which significantly enhanced tumoricidal effects of doxorubicin, by either co-administered as a physical mixture or as a targeting ligand covalently conjugated to the liposomal carrier. Given twice at an equivalent dose of 5 mg/kg, doxorubicin loaded liposomes modified with nRGD (nRGD-Lipo-Dox) showed excellent antitumor efficacy in 4T1 breast cancer mice, of which 44.4% remained alive for over 90 days without recurrence during the period of investigation. The dramatic improvement in antitumor efficacy was attributed to nRGD-Lipo-Dox which appeared to specifically interact with tumor vascular endothelial cells to achieve efficient tumor penetration, and modulate tumor microenvironment with depletion of tumor associated macrophages.

Keywords: Legumain; Tumor associated macrophage; Tumor microenvironment; iRGD; nRGD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / chemistry
  • Cell Line, Tumor
  • Doxorubicin / administration & dosage*
  • Drug Combinations
  • Drug Synergism*
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / pathology*
  • Oligopeptides / administration & dosage*
  • Oligopeptides / chemical synthesis
  • Protein Engineering / methods
  • Treatment Outcome
  • Tumor Microenvironment / drug effects*

Substances

  • Antibiotics, Antineoplastic
  • Drug Combinations
  • Oligopeptides
  • arginyl-glycyl-aspartic acid
  • Doxorubicin